Production (Stage)
Skye Bioscience, Inc.
SKYE
$1.99
-$0.21-9.55%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.92% | -150.02% | 50.67% | -57.44% | -13.57% |
| Total Depreciation and Amortization | 1.20% | 165.61% | 121.48% | 7.97% | -2.82% |
| Total Amortization of Deferred Charges | -- | -100.00% | -55.45% | 5.52% | 4.26% |
| Total Other Non-Cash Items | -2.89% | 186.38% | -225.89% | 56.44% | 210.07% |
| Change in Net Operating Assets | 46.93% | -180.26% | 169.61% | -20.97% | -1,063.11% |
| Cash from Operations | -12.39% | -55.30% | 25.81% | -50.67% | -22.46% |
| Capital Expenditure | 87.40% | 96.71% | -4,572.00% | -915.63% | 54.29% |
| Sale of Property, Plant, and Equipment | -- | 92.86% | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14,269.25% | 106.25% | -4,347.69% | -102.85% | 16,414.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 32,209.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 100.00% | -102.45% | 377,424.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.31% | -20.41% | 27.26% | -111.23% | 2,218.69% |